Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats

Cardiovascular Research

Volumn 94, Issue 1, 2012, Pages 96-104

  Wang, Hao ^a   Jessup, Jewell A ^a   Lin, Marina S ^a   Chagas, Clarissa ^a   Lindsey, Sarah H ^a   Groban, Leanne ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac hypertrophy; Diastolic dysfunction; GPR30; mRen2.Lewis rat; Post menopausal women

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALMODULIN; CALMODULIN 1; CALRETICULIN; CALSEQUESTRIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ESTRADIOL; G PROTEIN COUPLED RECEPTOR 30; MEMBRANE PROTEIN; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RYANODINE RECEPTOR 2; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CALCIUM EXCHANGE PROTEIN 1; SODIUM CALCIUM EXCHANGE PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRIADIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEART HYPERTROPHY; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HEART RATE; HEART VENTRICLE REMODELING; HEART WEIGHT; NONHUMAN; OVARIECTOMY; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING;

ANGIOTENSIN II; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CALCIUM; CARDIOTONIC AGENTS; CELL LINE; COLLAGEN; CYCLOPENTANES; ECHOCARDIOGRAPHY, DOPPLER; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HYPERTROPHY, LEFT VENTRICULAR; INJECTIONS, SUBCUTANEOUS; MICE; MYOCYTES, CARDIAC; NADPH OXIDASE; NATRIURETIC PEPTIDE, BRAIN; OVARIECTOMY; PHENOTYPE; QUINOLINES; RATS; RATS, INBRED LEW; RATS, TRANSGENIC; RECEPTORS, G-PROTEIN-COUPLED; RENIN; RNA, MESSENGER; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84859081581     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs090     Document Type: Article

References (68)

1. Oberman A, Prineas RJ, Larson JC, LaCroix A, Lasser NL. Prevalence and determinants of electrocardiographic left ventricular hypertrophy among a multiethnic population of postmenopausal women (The Women's Health Initiative). Am J Cardiol 2006; 97:512-519.
2. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002;4: 531-539.
3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-259.
4. Masoudi FA, Havranek EP, Smith G, Fish RH, Steiner JF, Ordin DL et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003;41:217-223.
5. Jessup M, Pinã IL. Is it important to examine gender differences in the epidemiology and outcome of severe heart failure? J Thorac Cardiovasc Surg 2004;127:1247-1252.
6. Harjai KJ, Nunez E, Stewart Humphrey J, Turgut T, Shah M, Newman J. Does gender bias exist in the medical management of heart failure? Int J Cardiol 2000;75:65-69.
7. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003;289:194-202.
8. Agabiti-Rosei E, Muiesan ML. Left ventricular hypertrophy and heart failure in women. J Hypertens Suppl 2002;20:S34-S38.
9. Cheng S, Xanthakis V, Sullivan LM, Lieb W, Massaro J, Aragam J et al. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation 2010;122:570-578.
10. Modena MG, Molinari R, Muia N Jr, Castelli A, Pala F, Rossi R. Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. Am J Hypertens 1999;12:1000-1008.
11. Fak AS, Erenus M, Tezcan H, Caymaz O, Oktay S, Oktay A. Effects of a single dose of oral estrogen on left ventricular diastolic function in hypertensive postmenopausal women with diastolic dysfunction. Fertil Steril 2000;73:66-71.
12. Jessup JA, Lindsey SH, Wang H, Chappell MC, Groban L. Attenuation of salt-induced cardiac remodeling and diastolic dysfunction by the GPER agonist G-1 in female mRen2.Lewis rats. PLoS One 2010;5:e15433.
13. Barton M, Meyer MR. Postmenopausal hypertension: mechanisms and therapy. Hypertension 2009;54:11-18.
14. McCubbin JA, Helfer SG, Switzer FS III, Price TM. Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease. Am Heart J 2002;143:711-717.
15. Garavaglia GE, Messerli FH, Schmieder RE, Nunez BD, Oren S. Sex differences in cardiac adaptation to essential hypertension. Eur Heart J 1989;10:1110-1114.
16. Brower GL, Gardner JD, Janicki JS. Gender mediated cardiac protection from adverse ventricular remodeling is abolished by ovariectomy. Mol Cell Biochem 2003;251: 89-95.
17. van Eickels M, GrohéC, Cleutjens JP, Janssen BJ, Wellens HJ, Doevendans PA. 17beta-estradiol attenuates the development of pressure-overload hypertrophy. Circulation 2001;104:1419-1423.
18. Xu Y, Arenas IA, Armstrong SJ, Davidge ST. Estrogen modulation of left ventricular remodeling in the aged heart. Cardiovasc Res 2003;57:388-394.
19. GrohéC, Kahlert S, Löbbert K, Stimpel M, Karas RH, Vetter H et al. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett 1997;416:107-112.
20. Deschamps AM, Murphy E. Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 2009;297: H1806-H1813.
21. Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007;148:3236-3245.
22. Revankar CM, Mitchell HD, Field AS, Burai R, Corona C, Ramesh C et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol 2007;2:536-544.
23. Olde B, Leeb-Lundberg LM. GPR30/GPER1: searching for a role in estrogen physiology. Trends Endocrinol Metab 2009;20:409-416.
24. Hazell GG, Yao ST, Roper JA, Prossnitz ER, O'Carroll AM, Lolait SJ. Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. J Endocrinol 2009;202:223-236.
25. Bopassa JC, Eghbali M, Toro L, Stefani E. A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2010;298:H16-H23.
26. Filice E, Recchia AG, Pellegrino D, Angelone T, Maggiolini M, Cerra MC. A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. J Physiol Pharmacol 2009;60:3-10.
27. Weil BR, Manukyan MC, Herrmann JL, Wang Y, Abarbanell AM, Poynter JA et al. Signaling via GPR30 protects the myocardium from ischemia/reperfusion injury. Surgery 2010;148:436-443.
28. Groban L, Yamaleyeva LM, Westwood BM, Houle TT, Lin M, Kitzman DW et al. Progressive diastolic dysfunction in the female mRen(2). Lewis rat: influence of salt and ovarian hormones. J Gerontol A Biol Sci Med Sci 2008;63:3-11.
29. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006;2:207-212.
30. Jessup JA, Zhang L, Presley TD, Kim-Shapiro DB,Wang H, Chen AF et al. Tetrahydrobiopterin restores diastolic function and attenuates superoxide production in ovariectomized mRen2.Lewis rats. Endocrinology 2011;152:2428-2436.
31. Jessup JA, Zhang L, Chen AF, Presley TD, Kim-Shapiro DB, Chappell MC et al. Neuronal nitric oxide synthase inhibition improves diastolic function and reduces oxidative stress in ovariectomized mRen2.Lewis rats. Menopause 2011;18:698-708.
32. Chappell MC, Gallagher PE, Averill DB, Ferrario CM, Brosnihan KB. Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat. Hypertension 2003;42:781-786.
33. Chappell MC, Westwood BM, Yamaleyeva LM. Differential effects of sex steroids in young and aged female mRen2.Lewis rats: a model of estrogen and salt-sensitive hypertension. Gend Med 2008;5(Suppl A):S65-S75.
34. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 2009;150:3753-3758.
35. Slama M, Susic D, Varagic J, Frohlich ED. Diastolic dysfunction in hypertension. Curr Opin Cardiol 2002;17:368-373.
36. Lee KS, Park JH, Lee S, Lim HJ, Park HY. PPARdelta activation inhibits angiotensin II induced cardiomyocyte hypertrophy by suppressing intracellular Ca2+ signaling pathway. J Cell Biochem 2009;106:823-834.
37. Patel VH, Chen J, Ramanjaneya M, Karteris E, Zachariades E, Thomas P et al. G-protein coupled estrogen receptor 1 expression in rat and human heart: Protective role during ischaemic stress. Int J Mol Med 2010;26:193-199.
38. Shuster LT, Gostout BS, Grossardt BR, Rocca WA. Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int 2008;14:111-116.
39. Amin MG, Tighiouart H, Weiner DE, Stark PC, Griffith JL, MacLeod B et al. Hematocrit and left ventricular mass: the Framingham Heart study. J Am Coll Cardiol 2004;43: 1276-1282.
40. Gaasch WH, Bing OH, Mirsky I. Chamber compliance and myocardial stiffness in left ventricular hypertrophy. Eur Heart J 1982;3(Suppl A):139-145.
41. Burlew BS, Weber KT. Cardiac fibrosis as a cause of diastolic dysfunction. Herz 2002; 27:92-98.
42. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-133.
43. Dubey RK, Gillespie DG, Jackson EK, Keller PJ. 17Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension 1998;31:522-528.
44. Voloshenyuk TG, Gardner JD. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females. Am J Physiol Regul Integr Comp Physiol 2010;299:R683-R693.
45. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004;94:1533-1542.
46. Jessup JA, Westwood BM, Chappell MC, Groban L. Dual ACE-inhibition and AT1 receptor antagonism improves ventricular lusitropy without affecting cardiac fibrosis in the congenic mRen2.Lewis rat. Ther Adv Cardiovasc Dis 2009;3:245-257.
47. Kravtsov GM, Kam KW, Liu J, Wu S, Wong TM. Altered Ca(2+) handling by ryanodine receptor and Na(+)-Ca(2+) exchange in the heart from ovariectomized rats: role of protein kinase A. Am J Physiol Cell Physiol 2007;292:C1625-C1635.
48. Ren J, Hintz KK, Roughead ZK, Duan J, Colligan PB, Ren BH et al. Impact of estrogen replacement on ventricular myocyte contractile function and protein kinase B/Akt activation. Am J Physiol Heart Circ Physiol 2003;284:H1800-H1807.
49. Chu SH, Goldspink P, Kowalski J, Beck J, Schwertz DW. Effect of estrogen on calciumhandling proteins, beta-adrenergic receptors, and function in rat heart. Life Sci 2006; 79:1257-1267.
50. Vizgirda VM, Wahler GM, Sondgeroth KL, Ziolo MT, Schwertz DW. Mechanisms of sex differences in rat cardiac myocyte response to beta-adrenergic stimulation. Am J Physiol Heart Circ Physiol 2002;282:H256-H263.
51. Klinge CM. Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem 2008;105:1342-1351.
52. Cazorla O, Freiburg A, Helmes M, Centner T, McNabb M, Wu Y et al. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res 2000;86:59-67.
53. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res 2010;106:1253-1264.
54. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci U S A 2010;107:15565-15570.
55. Martensson UE, Salehi SA, Windahl S, Gomez MF, Swärd K, Daszkiewicz-Nilsson J et al. Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 2009;150:687-698.
56. Mayer LP, Pearsall NA, Christian PJ, Devine PJ, Payne CM, McCuskey MK et al. Longterm effects of ovarian follicular depletion in rats by 4-vinylcyclohexene diepoxide. Reprod Toxicol 2002;16:775-781.
57. Kolodgie FD, Farb A, Litovsky SH, Narula J, Jeffers LA, Lee SJ et al. Myocardial protection of contractile function after global ischemia by physiologic estrogen replacement in the ovariectomized rat. J Mol Cell Cardiol 1997;29:2403-2414.
58. Cavasin MA, Sankey SS, Yu AL, Menon S, Yang XP. Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction. Am J Physiol Heart Circ Physiol 2003;284:H1560-H1569.
59. Modena MG, Muia N Jr, Aveta P, Molinari R, Rossi R. Effects of transdermal 17beta-estradiol on left ventricular anatomy and performance in hypertensive women. Hypertension 1999;34:1041-1046.
60. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
61. Furberg CD, Vittinghoff E, Davidson M, Herrington DM, Simon JA, Wenger NK et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation 2002;105:917-922.
62. Herrington DM. The HERS trial results: paradigms lost? Heart and Estrogen/progestin Replacement Study. Ann Intern Med 1999;131:463-466.
63. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
64. Heiss G, Wallace R, Anderson GL, Aragaki A, Beresford SA, Brzyski R et al. Health risk and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045.
65. Lacroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305: 1305-1314.
66. Yamaleyeva LM, Pendergrass KD, Pirro NT, Gallagher PE, Groban L, Chappell MC. Ovariectomy is protective against renal injury in the high-salt-fed older mRen2. Lewis rat. Am J Physiol Heart Circ Physiol 2007;293:H2064-H2071.
67. Yang CM, Kandaswamy V, Young D, Sen S. Changes in collagen phenotypes during progression and regression of cardiac hypertrophy. Cardiovasc Res 1997;36:236-245.
68. Pendergrass KD, Pirro NT,Westwood BM, Ferrario CM, Brosnihan KB, Chappell MC. Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats. Am J Physiol Heart Circ Physiol 2008;295: H10-H20.